Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer

BACKGROUND: Although COVID-19 severity in cancer patients is high, the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients undergoing chemotherapy for solid cancers in Japan have not been reported. METHODS: We investigated the safety and immunogenicity of BNT162b2 in 41 patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Funakoshi, Yohei, Yakushijin, Kimikazu, Ohji, Goh, Hojo, Wataru, Sakai, Hironori, Takai, Ryo, Nose, Taku, Ohata, Shinya, Nagatani, Yoshiaki, Koyama, Taiji, Kitao, Akihito, Nishimura, Meiko, Imamura, Yoshinori, Kiyota, Naomi, Harada, Kenichi, Tanaka, Yugo, Mori, Yasuko, Minami, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716153/
https://www.ncbi.nlm.nih.gov/pubmed/35090826
http://dx.doi.org/10.1016/j.jiac.2021.12.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716153/
https://www.ncbi.nlm.nih.gov/pubmed/35090826
http://dx.doi.org/10.1016/j.jiac.2021.12.021

Ejemplares similares